In a trial of 1,795 volunteers with early Alzheimer’s disease, the antibody drug lecanemab cut the pace of cognitive decline by 27% and of functional decline by 38% across eighteen months. The result, announced at the Clinical Trials in Alzheimer’s Disease conference, was the first strong test of an idea that John Hardy put forward three decades earlier.
Hardy was in the room. A write-up from the Sigrid Rausing Trust quotes him calling the Clarity AD results “the first truly positive mechanistic trial results in Alzheimer’s disease.” He also called the effect “modest but real.”
From a family with the disease to a hypothesis
The amyloid cascade hypothesis dates to 1992. The Trust says it grew from work with one family affected by inherited Alzheimer’s, in which Hardy’s team identified the earliest mutation behind a build-up of amyloid plaques. A profile on the Dementia Researcher site puts that discovery in 1991 and says it led directly to the hypothesis. Dates differ by a year between the two accounts. The idea is that amyloid protein triggers a sequence of events: faulty neuron activity, inflammation and aggregation of further proteins.
The hypothesis has shaped Alzheimer’s research for about 30 years, according to the Trust. Hardy was awarded the Breakthrough Prize in Life Sciences, and in 2018 shared the Brain Prize with Christian Haass, Bart De Strooper and Michel Goedert for what the prize citation called “groundbreaking research on the genetic and molecular basis of Alzheimer’s disease.” He was knighted in the 2022 New Year Honours.
A career across three countries
Hardy took a science degree at the University of Leeds in 1976 and a PhD at Imperial College London in 1981, on dopamine and amino acid neuropharmacology. Postdoctoral work followed at the MRC Neuropathogenesis Unit in Newcastle upon Tyne and then at the Swedish Brain Bank in Umea, where he began working on Alzheimer’s. By 1985 he was at St Mary’s Hospital, part of Imperial, and had started genetic studies of the disease.
In 1992 he took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida in Tampa. Four years later he moved to the Mayo Clinic in Jacksonville, where he became chair of neuroscience in 2000. In 2001 he joined the National Institute on Aging in Bethesda, Maryland, as chief of its laboratory of neurogenetics. Since 2007 he has held the Chair of Molecular Biology of Neurological Disease at University College London.
What lecanemab can and cannot do
Lecanemab, developed by Eisai and Biogen, is an antibody designed to direct the immune system to clear clumps of toxic beta-amyloid. It is given by intravenous infusion every two weeks, and patients must be treated early for the effect to count. It has side effects that call for close safety monitoring, and it is expensive.
Hardy argues the result should push researchers harder on the other two main Alzheimer’s pathologies, tau and neuroinflammation. The disease is the major cause of dementia, which affects around 900,000 people in the UK, based on a 2019 study by the Alzheimer’s Society and LSE. “This trial is an important first step,” Hardy said, “and I truly believe it represents the beginning of the end.”
Sources
- UCL research is the foundation for seminal breakthrough in Alzheimer's treatment (Sigrid Rausing Trust)
- Profile: Professor Sir John Hardy (Dementia Researcher / NIHR)





